NCT00003361View on ClinicalTrials.gov

Decitabine in Treating Patients With Myelodysplastic Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

April 30, 1998

Primary Completion Date

September 30, 2003

Study Completion Date

December 31, 2009

Conditions
LeukemiaMyelodysplastic Syndromes
Interventions
DRUG

decitabine

Trial Locations (3)

10021

Memorial Sloan-Kettering Cancer Center, New York

21231-2410

Johns Hopkins Oncology Center, Baltimore

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00003361 - Decitabine in Treating Patients With Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter